Celltrion Healthcare Canada

Since its inception in 2001, Celltrion Healthcare has grown into a global leader in biosimilars, operating in over 110 countries. The company aims to provide affordable, innovative treatments worldwide, recently expanding its reach to Canada. In 2021, Celltrion received Health Canada approval for Remsima™ SC, a subcutaneous treatment for rheumatoid arthritis, and Yuflyma®, a biosimilar to Humira® for various chronic inflammatory conditions. In 2023, Vegzelma™ was also approved for treating multiple cancers. Celltrion Healthcare continues to focus on expanding its portfolio and providing effective therapies to Canadian patients.